KRAS and malignant colon neoplasm: The interaction between GRB7 and PLK1 reactivates the MAPK pathway, suggesting that a combination therapy involving PLK1 and MEK inhibitors could be efficacious in overcoming this resistance, thereby presenting a new avenue for treating KRAS-mutated colon cancer.479 Zhou et al. demonstrated that variations in the expression of histone modification factors correlate with drug resistance in tumor cells, highlighting the heterogeneity among patients.